---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-070292"
form_type: "8-K"
ticker: "BDSX"
cik: "0001439725"
company_name: "BIODESIX INC"
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T14:40:31.626428+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Biodesix Q1 revenue $18M (+21% YoY); revises FY2025 guidance to $80-85M

## Summary
- Total Q1 2025 revenue $18.0M (+21% YoY); diagnostic testing $16.3M (+18%), development services $1.7M (+61%).
- Gross margin 79.4% (vs 78.6%); net loss $11.1M (improved 18% YoY); Adjusted EBITDA loss $6.2M (improved 11%).
- FY2025 revenue guidance revised to $80-85M due to ~1-quarter delay in sales expansion; still expects Q4 2025 Adj. EBITDA positivity.
- Drew $10M Tranche C from Perceptive Advisors loan, pro forma cash $27.6M; warrants exercise price modified to $0.4191/share.
- Operating expenses $23.4M (+3% YoY): R&D up $0.9M, SG&A down 1%; non-cash stock comp fell to $1.0M from $2.6M.

## SEC filing metadata
- accession: 0000950170-25-070292
- form_type: 8-K
- ticker: BDSX
- cik: 0001439725
- company_name: BIODESIX INC
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439725/000095017025070292/0000950170-25-070292-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439725/000095017025070292/bdsx-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-070292
- JSON: https://secwatch.observer/filing/0000950170-25-070292.json
- Plain text: https://secwatch.observer/filing/0000950170-25-070292.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.